An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy
We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case...
Gespeichert in:
| Veröffentlicht in: | Internal Medicine 2020/02/01, Vol.59(3), pp.395-399 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 399 |
|---|---|
| container_issue | 3 |
| container_start_page | 395 |
| container_title | Internal Medicine |
| container_volume | 59 |
| creator | Yoshizawa, Tsuyoshi Yamaguchi, Kenya Kawata, Nozomu Ryuzaki, Hitomi Ogawa, Masahiro Obinata, Daisuke Mochida, Junichi Takahashi, Satoru |
| description | We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of two cases with mCRPC that simultaneously investigated the ERG gene status and clinical aspects, including image evaluations and pathology. |
| doi_str_mv | 10.2169/internalmedicine.3302-19 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7028414</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2306493541</sourcerecordid><originalsourceid>FETCH-LOGICAL-c609t-b13669cfd2a0de2486ea176b5c394d23afea27438aa80dca8c6b34b94fbbe5273</originalsourceid><addsrcrecordid>eNplkc1uEzEUhUcIRNPCKyBLbNhM8d_M2BukKA0BKfwIFbG0PJ47GUcTu9gOVZ6hL42nKRGUjW35fPf4-p6iQARfUlLLt9YlCE6PO-issQ4uGcO0JPJJMSOMy7KhrHpazLAkoqR5OSvOY9xizEQj6fPijJGayEqKWXE3d2j5bYVW4ADNs-Uh2oisQ9e3Hi10hIhubRrQJ0g6Jp2smW5TyCfvygCZTtol9DX4SYasOgNhcvgxWDOgeWszDMFn_yvYeXdfDB1ae7cps7BDy763RpvDi-JZr8cILx_2i-L7--X14kO5_rL6uJivS1NjmcqWsLqWpu-oxh1QLmrQpKnbyjDJO8p0D5o2nAmtBe6MFqZuGW8l79sWKtqwi-Ld0fdm3-YJGnC5pVHdBLvT4aC8tupfxdlBbfwv1WAqOOHZ4M2DQfA_9xCT2tloYBy1A7-PijJcc8kqTjL6-hG69fspuoniUjQN4VNH4kiZPMYYoD81Q7CaElePE1dT4orIXPrq78-cCv9EnIHPR2CbA9rACdAhhznC_86VVOx-Ob5wAs2ggwLHfgOrnczd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2349877147</pqid></control><display><type>article</type><title>An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy</title><source>J-STAGE Free</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Yoshizawa, Tsuyoshi ; Yamaguchi, Kenya ; Kawata, Nozomu ; Ryuzaki, Hitomi ; Ogawa, Masahiro ; Obinata, Daisuke ; Mochida, Junichi ; Takahashi, Satoru</creator><creatorcontrib>Yoshizawa, Tsuyoshi ; Yamaguchi, Kenya ; Kawata, Nozomu ; Ryuzaki, Hitomi ; Ogawa, Masahiro ; Obinata, Daisuke ; Mochida, Junichi ; Takahashi, Satoru</creatorcontrib><description>We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of two cases with mCRPC that simultaneously investigated the ERG gene status and clinical aspects, including image evaluations and pathology.</description><identifier>ISSN: 0918-2918</identifier><identifier>EISSN: 1349-7235</identifier><identifier>DOI: 10.2169/internalmedicine.3302-19</identifier><identifier>PMID: 31619598</identifier><language>eng</language><publisher>Japan: The Japanese Society of Internal Medicine</publisher><subject>abiraterone ; Case Report ; Castration ; Chemotherapy ; Clinical aspects ; durable complete response ; ERG gene ; Fluorescence in situ hybridization ; Internal medicine ; Metastases ; Metastasis ; metastatic castration-resistant prostate cancer ; Prostate cancer</subject><ispartof>Internal Medicine, 2020/02/01, Vol.59(3), pp.395-399</ispartof><rights>2020 by The Japanese Society of Internal Medicine</rights><rights>Copyright Japan Science and Technology Agency 2020</rights><rights>Copyright © 2020 by The Japanese Society of Internal Medicine</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c609t-b13669cfd2a0de2486ea176b5c394d23afea27438aa80dca8c6b34b94fbbe5273</citedby><cites>FETCH-LOGICAL-c609t-b13669cfd2a0de2486ea176b5c394d23afea27438aa80dca8c6b34b94fbbe5273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028414/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7028414/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1883,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31619598$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoshizawa, Tsuyoshi</creatorcontrib><creatorcontrib>Yamaguchi, Kenya</creatorcontrib><creatorcontrib>Kawata, Nozomu</creatorcontrib><creatorcontrib>Ryuzaki, Hitomi</creatorcontrib><creatorcontrib>Ogawa, Masahiro</creatorcontrib><creatorcontrib>Obinata, Daisuke</creatorcontrib><creatorcontrib>Mochida, Junichi</creatorcontrib><creatorcontrib>Takahashi, Satoru</creatorcontrib><title>An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy</title><title>Internal Medicine</title><addtitle>Intern. Med.</addtitle><description>We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of two cases with mCRPC that simultaneously investigated the ERG gene status and clinical aspects, including image evaluations and pathology.</description><subject>abiraterone</subject><subject>Case Report</subject><subject>Castration</subject><subject>Chemotherapy</subject><subject>Clinical aspects</subject><subject>durable complete response</subject><subject>ERG gene</subject><subject>Fluorescence in situ hybridization</subject><subject>Internal medicine</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>metastatic castration-resistant prostate cancer</subject><subject>Prostate cancer</subject><issn>0918-2918</issn><issn>1349-7235</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNplkc1uEzEUhUcIRNPCKyBLbNhM8d_M2BukKA0BKfwIFbG0PJ47GUcTu9gOVZ6hL42nKRGUjW35fPf4-p6iQARfUlLLt9YlCE6PO-issQ4uGcO0JPJJMSOMy7KhrHpazLAkoqR5OSvOY9xizEQj6fPijJGayEqKWXE3d2j5bYVW4ADNs-Uh2oisQ9e3Hi10hIhubRrQJ0g6Jp2smW5TyCfvygCZTtol9DX4SYasOgNhcvgxWDOgeWszDMFn_yvYeXdfDB1ae7cps7BDy763RpvDi-JZr8cILx_2i-L7--X14kO5_rL6uJivS1NjmcqWsLqWpu-oxh1QLmrQpKnbyjDJO8p0D5o2nAmtBe6MFqZuGW8l79sWKtqwi-Ld0fdm3-YJGnC5pVHdBLvT4aC8tupfxdlBbfwv1WAqOOHZ4M2DQfA_9xCT2tloYBy1A7-PijJcc8kqTjL6-hG69fspuoniUjQN4VNH4kiZPMYYoD81Q7CaElePE1dT4orIXPrq78-cCv9EnIHPR2CbA9rACdAhhznC_86VVOx-Ob5wAs2ggwLHfgOrnczd</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Yoshizawa, Tsuyoshi</creator><creator>Yamaguchi, Kenya</creator><creator>Kawata, Nozomu</creator><creator>Ryuzaki, Hitomi</creator><creator>Ogawa, Masahiro</creator><creator>Obinata, Daisuke</creator><creator>Mochida, Junichi</creator><creator>Takahashi, Satoru</creator><general>The Japanese Society of Internal Medicine</general><general>Japan Science and Technology Agency</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200201</creationdate><title>An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy</title><author>Yoshizawa, Tsuyoshi ; Yamaguchi, Kenya ; Kawata, Nozomu ; Ryuzaki, Hitomi ; Ogawa, Masahiro ; Obinata, Daisuke ; Mochida, Junichi ; Takahashi, Satoru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c609t-b13669cfd2a0de2486ea176b5c394d23afea27438aa80dca8c6b34b94fbbe5273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>abiraterone</topic><topic>Case Report</topic><topic>Castration</topic><topic>Chemotherapy</topic><topic>Clinical aspects</topic><topic>durable complete response</topic><topic>ERG gene</topic><topic>Fluorescence in situ hybridization</topic><topic>Internal medicine</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>metastatic castration-resistant prostate cancer</topic><topic>Prostate cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoshizawa, Tsuyoshi</creatorcontrib><creatorcontrib>Yamaguchi, Kenya</creatorcontrib><creatorcontrib>Kawata, Nozomu</creatorcontrib><creatorcontrib>Ryuzaki, Hitomi</creatorcontrib><creatorcontrib>Ogawa, Masahiro</creatorcontrib><creatorcontrib>Obinata, Daisuke</creatorcontrib><creatorcontrib>Mochida, Junichi</creatorcontrib><creatorcontrib>Takahashi, Satoru</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Internal Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoshizawa, Tsuyoshi</au><au>Yamaguchi, Kenya</au><au>Kawata, Nozomu</au><au>Ryuzaki, Hitomi</au><au>Ogawa, Masahiro</au><au>Obinata, Daisuke</au><au>Mochida, Junichi</au><au>Takahashi, Satoru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy</atitle><jtitle>Internal Medicine</jtitle><addtitle>Intern. Med.</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>59</volume><issue>3</issue><spage>395</spage><epage>399</epage><pages>395-399</pages><issn>0918-2918</issn><eissn>1349-7235</eissn><abstract>We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of two cases with mCRPC that simultaneously investigated the ERG gene status and clinical aspects, including image evaluations and pathology.</abstract><cop>Japan</cop><pub>The Japanese Society of Internal Medicine</pub><pmid>31619598</pmid><doi>10.2169/internalmedicine.3302-19</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0918-2918 |
| ispartof | Internal Medicine, 2020/02/01, Vol.59(3), pp.395-399 |
| issn | 0918-2918 1349-7235 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7028414 |
| source | J-STAGE Free; PubMed Central Open Access; PubMed Central |
| subjects | abiraterone Case Report Castration Chemotherapy Clinical aspects durable complete response ERG gene Fluorescence in situ hybridization Internal medicine Metastases Metastasis metastatic castration-resistant prostate cancer Prostate cancer |
| title | An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A52%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20ERG%20Gene%20Analysis%20in%20Two%20Cases%20with%20Metastatic%20Castration-resistant%20Prostate%20Cancer%20in%20Which%20Abiraterone%20Demonstrated%20Long-term%20Efficacy&rft.jtitle=Internal%20Medicine&rft.au=Yoshizawa,%20Tsuyoshi&rft.date=2020-02-01&rft.volume=59&rft.issue=3&rft.spage=395&rft.epage=399&rft.pages=395-399&rft.issn=0918-2918&rft.eissn=1349-7235&rft_id=info:doi/10.2169/internalmedicine.3302-19&rft_dat=%3Cproquest_pubme%3E2306493541%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2349877147&rft_id=info:pmid/31619598&rfr_iscdi=true |